NCT00437372

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.

Detailed description

The combination of ionizing radiation and antiangiogenic agents seems to be a counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a reduction in oxygen concentration would be expected following a reduction in tumor vasculature after antiangiogenic treatment.

Conditions

• Cancer
• Head and Neck Cancer
• Pelvic Cancer
• Nervous System Neoplasms
• Thoracic Neoplasms

Interventions

Type	Name	Description
DRUG	Sunitinib	The use of the FDA approved drug sunitinib, used in an "off-label" manner with external beam radiation therapy.
RADIATION	External Beam Radiation Therapy	Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.

Timeline

• Start date: 2007-03-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2007-02-21
• Last updated: 2025-05-02

Locations

1 site across 1 country: United States